Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04044859 · ClinicalTrials.gov registry record · Phase 1
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
A Phase 1 study of Ovarian Cancer and Melanoma, sponsored by Uswm CT.
- Active
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
- 17
- Study locations
NCT04044859 is a Phase 1 study of Ovarian Cancer and Melanoma that is active but no longer recruiting, run by Uswm CT. The registered enrollment target is 120 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (84% lower). The trial reports 17 study locations across 14 states.
The verdict
NCT04044859, a Phase 1 study of Ovarian Cancer and Melanoma, is active but no longer recruiting, sponsored by Uswm CT.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
- 17
- Study locations
Study Summary
This study will investigate the safety and tolerability of ADP-A2M4CD8 T-cell therapy in subjects who have the appropriate human leukocyte antigen (HLA) and MAGE-A4 tumor antigen. Tumor indications include endometrial, esophageal, esophagogastric junction (EGJ), gastric, head and neck, melanoma, non-small cell lung (NSCLC), ovarian or urothelial cancer.
Conditions Studied
Interventions
- GENETIC Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks
Study Locations (17)
Other
- Hospital Universitario Vall d'Hebron - Barcelona
- Hospital Universitario Fundacion Jimenez Diaz - Madrid
- Hospital Universitario HM Sanchinarro CIOCC - Madrid
- Hospital Universitario Virgen del Rocio - Seville
Florida
- Name of Institution: Orlando Health Cancer Institute - Orlando
Massachusetts
- Massachusetts General Hospital - Boston
Missouri
- Washington University - School of Medicine - St Louis
New York
- Memorial Sloan Kettering Cancer Center - New York
North Carolina
- Duke University Medical Center, Duke Cancer Institute - Durham
Oklahoma
- OU Health Stephenson Cancer Center - Oklahoma City
Tennessee
- Sarah Cannon Research Institute - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2019-08-20 |
| Est. Completion | 2037-04-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04044859
The ClinicalTrials.gov registry entry for NCT04044859 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (84% lower). The listed sponsor is Uswm CT, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks is the first listed.
NCT04044859 reports 17 study locations spanning 14 distinct geographic areas - top geographies include Other, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04044859 about?
NCT04044859 is a clinical study titled "ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)". This study will investigate the safety and tolerability of ADP-A2M4CD8 T-cell therapy in subjects who have the appropriate human leukocyte antigen (HLA) and MAGE-A4 tumor antigen. Tumor indications include endometrial, esophageal, esophagogastric junction (EGJ), gastric, head and neck, melanoma, non...
What is the current status of trial NCT04044859?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2019-08-20. Estimated completion is 2037-04-30.
What conditions does trial NCT04044859 study?
This clinical trial studies the following conditions: Ovarian Cancer, Melanoma, Head and Neck Cancer, Endometrial Cancer, Esophageal Cancer.
What interventions are being tested in trial NCT04044859?
The interventions under investigation include: Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks (GENETIC).
Who is sponsoring clinical trial NCT04044859?
This trial is sponsored by Uswm CT, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04044859 being conducted?
This trial has 17 study locations across Florida, Massachusetts, Missouri, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.